Specialized Program Of Research Excellence (SPORE) in Leukemia.

白血病专业卓越研究计划 (SPORE)。

• 批准号: 10194393
• 负责人: Daniel C Link
• 金额: $ 203.6万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-03 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10194393
• 关键词: AML/MDS; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute T Cell Leukemia; Allogenic; Animal Model; Antibody Therapy; Basic Science; Biometry; Bispecific Antibodies; CD3 Antigens; CXCR4 gene; Cancer Research Project; Clinical; Clinical Trials; Collaborations; Data; Decitabine; Development; Disabled Persons; Dysmyelopoietic Syndromes; Female; Genomics; Goals; Grant Review; Hematopoiesis; Immunology; Immunotherapy; Infrastructure; Institution; Joints; Laboratories; Memory; Mentors; Minority; Molecular; Molecular Profiling; Multi-Institutional Clinical Trial; Mutate; Mutation; Natural Killer Cells; Nelarabine; Oral; Pathway interactions; Patients; Program Reviews; Property; RNA Splicing; Refractory; Relapse; Research; Research Personnel; Research Project Grants; Resistance; Resources; Salvage Therapy; Signal Transduction; Specialized Program of Research Excellence; TP53 gene; Testing; Therapeutic; Therapeutic Trials; Training; Training Programs; Translational Research; Universities; Washington; acute T-cell lymphoblastic leukemia cell; antibody conjugate; base; cancer genomics; career; conditioning; cytokine; first-in-human; fundamental research; hematopoietic cell transplantation; inhibitor/antagonist; innovation; leukemia; leukemia treatment; meetings; mutant; novel; novel marker; novel therapeutics; peer; pre-clinical; preclinical study; programs; recruit; research and development; response; targeted agent; targeted treatment; translational cancer research

ABSTRACT The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long-term goal is to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes and to develop and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed. Aim 1. We will exploit institutional expertise in cancer genomics, immunology, and hematopoiesis to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes. Basic research at WUSM has led to the development of the following five translational research projects, all featuring innovative investigator-initiated therapeutic trials for leukemias or MDS. · Project 1. Molecular determinants of decitabine responsiveness · Project 2. Targeted therapies for T cell acute lymphoblastic leukemia (T-ALL) · Project 3. Novel therapies for splicesome-mutant MDS · Project 4. Bi-specific antibody-based therapies for AML · Project 5. Memory-like NK cell augmented hematopoietic cell transplantation for AML Aim 2. We will enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B. Biostatistics; and 3) Core C. Administration. Aim 3. We will recruit and train new investigators in translational research. This SPORE will support a Career Enhancement Program (CEP) to recruit and mentor new investigators in translational leukemia research. The SPORE has established a successful minority post-baccalaureate training program. The SPORE also will support a Developmental Research Program (DRP) to support innovative translational concepts. Aim 4. We will facilitate inter-SPORE collaboration. Four of the SPORE projects include multi-institutional clinical trials, including three at other Leukemia SPORE institutions. We have established CEP educational exchange and grant review programs with peer Leukemia SPORE institutions. We will continue to organize and participate in joint meetings of Leukemia SPOREs at MD Anderson and Harvard.

摘要 华盛顿大学的白血病孢子是一个高度动态的转化癌症研究计划， 特别关注白血病和骨髓增生异常综合征（MDS）。我们召集了一个杰出的 一组在基础和临床白血病研究方面具有互补专长的研究人员。在这次活动中，我们 利用癌症基因组学、免疫学和造血学方面的专业知识， 白血病的研究我们的长期目标是开发新型白血病生物标志物和治疗方法， 骨髓增生异常综合征和发展和促进创新的转化白血病研究。实现 为了实现这些目标，提出了以下具体目标。 目标1。我们将利用癌症基因组学、免疫学和造血学方面的机构专业知识， 为白血病和骨髓增生异常综合征开发新的生物标志物和治疗方法。基础研究 在WUSM已经导致了以下五个转化研究项目的发展，所有具有创新性 研究者发起的白血病或骨髓增生异常综合症治疗试验。 ·项目1。地西他滨反应性的分子决定因素 ·项目2。T细胞急性淋巴细胞白血病（T-ALL）的靶向治疗 ·项目3。剪接体突变型MDS的新疗法 ·项目4。基于双特异性抗体的AML治疗 ·项目5。记忆样NK细胞辅助造血细胞移植治疗急性髓细胞白血病 目标2.我们将加强支持转化性白血病研究的基础设施。这个孢子 将支持以下共享研究资源：1）核心A。生物样本处理; 2）核心B。 生物统计学; 3）核心C。局 目标3.我们将招募和培训新的翻译研究人员。此孢子将支持 职业提升计划（CEP），招募和指导新的研究人员在转化白血病 research. SPRE已经建立了一个成功的少数民族学士后培训方案。孢子 还将支持发展研究计划（DRP），以支持创新的转化概念。 目标4。我们将促进SPORE之间的合作。四个SPORE项目包括多机构 临床试验，包括其他白血病孢子机构的三项临床试验。我们已经建立了CEP教育 与Leukemia SPORE同行机构开展交流和赠款审查计划。我们将继续组织和 参加MD安德森和哈佛的白血病孢子联合会议。